InvestorsHub Logo
Followers 188
Posts 28939
Boards Moderated 1
Alias Born 08/29/2012

Re: sharkey1 post# 389032

Monday, 10/16/2023 9:41:25 AM

Monday, October 16, 2023 9:41:25 AM

Post# of 402481
X 1. Adderall IR $335 Million
X 2. In house marketing and distribution: Kirkov
X 3. Generic OxyContin- FIRST TO FILE Aug 17, 2023 $720 Million
—4. Full ownership of Adderall XR $ 1.56 Billion
—5. Generic Concerta- $1.2 BILLION
—6. Generic Vyvanse- $5.3 BILLION
—7. Vigabatrin - VigPoder approved Pyros $233 Million
—8. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
—9. Patented Unique ADF (w/o naltrexone)-- NDA
—10. Mikah ANDA (s)
—11. Undisclosed (s)
—12. Antimetabolite ANDA- Methotrexate -$600 Million
—13. Undisclosed Antimetabolite ANDA- $42 Million
—14. Prasco/Burel Adderall agreement January 1st 2024
—15. Dexcel partnership approval by Israeli Health for European distribution
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News